Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HTR1B | P28222 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24920165 | 0.85 | MEN1 (0.37) | MEN1ALDH1A1KMT2ATSHR | |
| SCHEMBL9706139 | 0.83 | HTR1B (0.40) | MEN1KMT2ATSHRHTR1B | |
| SCHEMBL19194672 | 0.83 | TSHR (0.41) | MEN1ALDH1A1KMT2ATSHR | |
| SCHEMBL5322174 | 0.79 | MEN1 (0.50) | MEN1ALDH1A1KMT2ATSHR | |
| SCHEMBL27361642 | 0.79 | HTR1B (0.38) | MEN1KMT2AHTR1B | |
| SCHEMBL17159543 | 0.79 | HTR1B (0.42) | MEN1KMT2ATSHRHTR1B | |
| SCHEMBL26951234 | 0.77 | TSHR (0.33) | MEN1ALDH1A1KMT2ATSHR | |
| SCHEMBL9705221 | 0.77 | DNM1 (0.39) | MEN1KMT2ATSHR | |
| SCHEMBL3426567 | 0.77 | — | — | |
| SCHEMBL11416101 | 0.74 | HTR1B (0.40) | MEN1ALDH1A1KMT2AHTR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8003632-B2 | administerine tacrine, a tacrine analog, fasciculin, metrifonate, heptyl-physostigmine, norpyridostigmine, norneostigmine, huperzine A or an analogue, physostigmine, heptyl-physostigmine etc. free of galantamine to reduce the level of a proinflammatory cytokine | THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH (US) | 2011-08-23 | — | — | US | disclosed |
| US-20080070901-A1 | Cholineterase inhibitors for treating inflammation | THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH | 2008-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070901-A1 | Cholineterase inhibitors for treating inflammation | ACHE, BCHE, CHAT | MEN1 4185/4885ALDH1A1 867/4885KMT2A 2173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.